New treatment for skin cancer using microneedles to deliver immunotherapy
Project 3: Localized microneedle-directed combination immunotherapy for cSCC
This study is testing a new way to treat skin cancer by using tiny microneedles to deliver a special medicine right to the tumor, which could help your body fight the cancer better while causing fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10926846 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat cutaneous squamous cell carcinomas (cSCCs) by using a microneedle array to deliver a combination of a chemotherapy agent and an immune stimulant directly to the tumor site. The microneedles dissolve in the skin, allowing for localized treatment that minimizes side effects typically associated with systemic therapies. By targeting the tumor microenvironment, this method aims to enhance the immune response against cancer cells while reducing the risk of adverse effects. The goal is to create a more effective and personalized treatment option for patients with skin cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cutaneous squamous cell carcinoma, particularly those who may benefit from localized immunotherapy.
Not a fit: Patients with advanced or metastatic skin cancer or those who do not have cutaneous squamous cell carcinoma may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with skin cancer, potentially improving outcomes and quality of life.
How similar studies have performed: This approach is innovative and represents a novel application of microneedle technology in cancer treatment, with limited prior studies demonstrating similar localized immunotherapy strategies.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Falo, Louis D — University of Pittsburgh at Pittsburgh
- Study coordinator: Falo, Louis D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.